Early Diagnosis and Treatment of Rheumatoid Arthritis

被引：281

作者：

Littlejohn, Emily A. ^{[1
]}

Monrad, Seetha U. ^{[2
]}

机构：

[1] Cleveland Clin, Orthopaed & Rheumatol Inst, Rheumatol & Immunol Dis, 9500 Euclid Ave,A50, Cleveland, OH 44195 USA

[2] Michigan Med, Div Rheumatol, 7D08 North Ingalls Bldg,300 North Ingalls St, Ann Arbor, MI 48109 USA

来源：

PRIMARY CARE | 2018年 / 45卷 / 02期

关键词：

Rheumatoid arthritis; Synovitis; Extra-articular manifestations; Diagnostic criteria; Disease-modifying antirheumatic drugs; Biologic agents; CYCLIC CITRULLINATED PEPTIDE; DOUBLE-BLIND; PLUS METHOTREXATE; THERAPY; DISEASE; COMBINATION; ANTIBODIES; MORTALITY; EROSIONS; COHORT;

D O I：

10.1016/j.pop.2018.02.010

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Rheumatoid arthritis is the most common inflammatory arthritis and a significant cause of morbidity and mortality. Primary care providers should be able to distinguish the clinical presentation of rheumatoid arthritis from that of osteoarthritis, because the treatment and outcomes differ greatly between these 2 common forms of arthritis. This article provides a current overview of our understanding of rheumatoid arthritis, with an emphasis on early diagnosis and approaches to treatment.

引用

收藏

页码：237 / +

页数：20

相关论文

共 66 条

[11] Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses [J].

Behrens, Frank ;

Koehm, Michaela ;

Burkhardt, Harald .

CURRENT OPINION IN RHEUMATOLOGY, 2011, 23 (03) :282-287

[12] Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset [J].

Berglin, E ;

Johansson, T ;

Sundin, U ;

Jidell, E ;

Wadell, G ;

Hallmans, G ;

Rantapää-Dahlqvist, S .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (04) :453-458

[13] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[14] The influence of ageing on the development and management of rheumatoid arthritis [J].

Boots, Annemieke M. H. ;

Maier, Andrea B. ;

Stinissen, Piet ;

Masson, Pierre ;

Lories, Rik J. ;

De Keyser, Filip .

NATURE REVIEWS RHEUMATOLOGY, 2013, 9 (10) :604-613

[15] The use of methotrexate in rheumatoid arthritis [J].

Borchers, AT ;

Keen, CL ;

Cheema, GS ;

Gershwin, ME .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2004, 34 (01) :465-483

[16] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].

Breedveld, FC ;

Weisman, MH ;

Kavanaugh, AF ;

Cohen, SB ;

Pavelka, K ;

van Vollenhoven, R ;

Sharp, J ;

Perez, JL ;

Spencer-Green, GT .

ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37

[17] Evidence that cytokines play a role in rheumatoid arthritis [J].

Brennan, Fionula M. ;

McInnes, Iain B. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (11) :3537-3545

[18] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].

Clair, EWS ;

van der Heijde, DMFM ;

Smolen, JS ;

Maini, RN ;

Bathon, JM ;

Emery, P ;

Keystone, E ;

Schiff, M ;

Kalden, JR ;

Wang, B ;

DeWoody, K ;

Weiss, R ;

Baker, D .

ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443

[19] Extremity Magnetic Resonance Imaging in Rheumatoid Arthritis: Updated Literature Review [J].

Cohen, Stanley B. ;

Potter, Hollis ;

Deodhar, Atul ;

Emery, Paul ;

Conaghan, Philip ;

Ostergaard, Mikkel .

ARTHRITIS CARE & RESEARCH, 2011, 63 (05) :660-665

[20]

Cojocaru Manole, 2010, Maedica (Bucur), V5, P286

← 1 2 3 4 5 6 7 →